Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel as salvage treatment for cisplatin‑resistant germ cell cancer
2012-004418-32Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jul 2014
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in germ cell tumor (GCT), testicular cancer and extragonadal germ cell tumor (EGGCT), sponsored by Oslo University Hospital. Primary endpoint: Objective response rate. Started Jul 2014; status: completed.
02
Drugs
cabazitaxel
03
Conditions
germ cell tumor (GCT)testicular cancerextragonadal germ cell tumor (EGGCT)
Beyond the preview
Go deeper on 2012-004418-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004418-32.